Log In
Print this Print this

Xadago, safinamide

Also known as: formerly PNU-151774E

  Manage Alerts
Collapse Summary General Information
Company Newron Pharmaceuticals S.p.A.
DescriptionAlpha-aminoamide derivative that acts as a reversible monoamine oxidase B (MAO-B) and dopamine reuptake inhibitor while reducing glutamatergic activity
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat early Parkinson's disease (PD); Treat mid- to late-stage Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation EU - Standard Review (Treat Parkinson's disease (PD));
Switzerland - Standard Review (Treat Parkinson's disease (PD))
PartnerMeiji Seika Pharma Co. Ltd.;
US WorldMeds LLC;
Zambon Co. S.p.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today